Search results for "Breast"

showing 10 items of 1871 documents

Circadian Rhythm and Concentration of Melatonin in Breast Cancer Patients

2020

Background: Melatonin is a biomarker of the central circadian clock and its chronobiotic actions entraining circadian rhythms to the light-dark cycle are well known. Reduction in melatonin levels and altered circadian rhythms have been associated with a high risk of breast cancer. Melatonin has also shown to display anti-proliferative effects on breast cancer growth and proliferation. Evaluation of melatonin circadian rhythm alterations in patients bearing breast cancer may have interesting prognostic and therapeutic applications. Objective: To review studies evaluating the circadian rhythm of melatonin in breast cancer patients. The effects of surgery and chemotherapy on melatonin secreti…

0301 basic medicineEndocrinology Diabetes and MetabolismBreast surgerymedicine.medical_treatmentChronobioticCircadian clockEstrogen receptorPhysiologyBreast Neoplasms030209 endocrinology & metabolismHistory 21st CenturyAntioxidantsMelatonin03 medical and health sciences0302 clinical medicineBreast cancermedicineHumansImmunology and AllergyCircadian rhythmMelatoninbusiness.industrymedicine.diseaseCircadian RhythmSleep Quality030104 developmental biologyQuality of LifeBiomarker (medicine)FemaleSleepbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugEndocrine, Metabolic & Immune Disorders - Drug Targets
researchProduct

Timing of complementary feeding and associations with maternal and infant characteristics: A Norwegian cross-sectional study.

2018

Norwegian Health authorities recommend solid food to be introduced between child age 4-6 months, depending on both the mother´s and infant's needs. The aim of this paper is to describe timing of complementary feeding in a current sample of Norwegian mother/infant-dyads and explore potential associations between timing of introduction to solid foods and a wide range of maternal and infant characteristics known from previous literature to influence early feeding interactions. The paper is based on data from the Norwegian randomized controlled trial Early Food for Future Health. In 2016, a total of 715 mothers completed a web-based questionnaire at child age 5.5 months. We found that 5% of the…

0301 basic medicineEuropean PeopleTime FactorsPhysiologyCross-sectional studyMaternal Healthlcsh:MedicinePediatricslaw.inventionFamiliesRandomized controlled triallawMedicine and Health SciencesEthnicitiesMedicinePublic and Occupational HealthYoung adultInfant Nutritional Physiological Phenomenalcsh:ScienceChildrenBreast Milkmedia_commonMultidisciplinaryNorwayNutrition SurveysSocioeconomic Aspects of HealthBody FluidsBreast FeedingMilklanguageFemaleInfant FoodAnatomyInfantsResearch ArticleAdultAdolescentNorwegian Peoplemedia_common.quotation_subjectMothersNorwegianBreast milkBeveragesYoung Adult03 medical and health sciencesHumansGirlInfant Nutritional Physiological PhenomenaNutrition030109 nutrition & dieteticsbusiness.industrylcsh:RBiology and Life SciencesInfantlanguage.human_languageDietHealth CareCross-Sectional StudiesAge GroupsFoodPeople and PlacesWomen's HealthPopulation Groupingslcsh:QNeonatologybusinessBreast feedingDemographyPLoS ONE
researchProduct

Integrative analysis of structural variations using short-reads and linked-reads yields highly specific and sensitive predictions.

2020

Genetic diseases are driven by aberrations of the human genome. Identification of such aberrations including structural variations (SVs) is key to our understanding. Conventional short-reads whole genome sequencing (cWGS) can identify SVs to base-pair resolution, but utilizes only short-range information and suffers from high false discovery rate (FDR). Linked-reads sequencing (10XWGS) utilizes long-range information by linkage of short-reads originating from the same large DNA molecule. This can mitigate alignment-based artefacts especially in repetitive regions and should enable better prediction of SVs. However, an unbiased evaluation of this technology is not available. In this study, w…

0301 basic medicineFalse discovery rateComputer scienceArtificial Gene Amplification and ExtensionPolymerase Chain ReactionDatabase and Informatics MethodsSequencing techniques0302 clinical medicineBreast TumorsBasic Cancer ResearchMedicine and Health SciencesDNA sequencingBiology (General)EcologyHigh-Throughput Nucleotide SequencingGenomicsDNA Neoplasm3. Good healthIdentification (information)OncologyComputational Theory and MathematicsModeling and SimulationMCF-7 CellsFemaleSequence AnalysisResearch ArticleBioinformaticsQH301-705.5Breast NeoplasmsGenomicsComputational biologyResearch and Analysis MethodsHuman Genomics03 medical and health sciencesCellular and Molecular NeuroscienceCancer GenomicsGenomic MedicineBreast CancerGeneticsDNA Barcoding TaxonomicHumansMolecular Biology TechniquesMolecular BiologyEcology Evolution Behavior and SystematicsWhole genome sequencingLinkage (software)Whole Genome SequencingGenome HumanDideoxy DNA sequencingGenetic Diseases InbornCancers and NeoplasmsBiology and Life SciencesComputational BiologyStatistical modelSequence Analysis DNARepetitive RegionsLogistic Models030104 developmental biologyGenomic Structural VariationHuman genomeSequence Alignment030217 neurology & neurosurgeryPLoS Computational Biology
researchProduct

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

2020

Abstract HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with HER2-mutant metastatic breast cancer. Overall response rate was similar with or without estrogen receptor (ER) blockade. By comparison, progression-free survival and duration of response appeared longer in ER+ patients receiving combination therapy, although the study was not designed for direct comparison. Preexistent concurrent activating HER2 or HER3 alterations were associated with poor treatment outcome. Similarly, acquisition of m…

0301 basic medicineFulvestrantCombination therapybusiness.industryEstrogen receptormedicine.diseaseMetastatic breast cancer03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerOncologyTrastuzumab030220 oncology & carcinogenesisNeratinibmedicineCancer researchSignal transductionskin and connective tissue diseasesbusinessmedicine.drugCancer Discovery
researchProduct

Retrospective Proteomic Screening of 100 Breast Cancer Tissues.

2017

The present investigation has been conducted on one hundred tissue fragments of breast cancer, collected and immediately cryopreserved following the surgical resection. The specimens were selected from patients with invasive ductal carcinoma of the breast, the most frequent and potentially aggressive type of mammary cancer, with the objective to increase the knowledge of breast cancer molecular markers potentially useful for clinical applications. The proteomic screening; by 2D-IPG and mass spectrometry; allowed us to identify two main classes of protein clusters: proteins expressed ubiquitously at high levels in all patients; and proteins expressed sporadically among the same patients. Wit…

0301 basic medicineGene isoformClinical Biochemistrygel-based proteomiclcsh:QR1-502Motilitysurgical tissuegel-based proteomicsBiologyBioinformaticsProteomicsBiochemistrylcsh:MicrobiologyArticleMetastasis03 medical and health sciencesBreast cancerbreast cancerStructural BiologyMedicineSettore BIO/06 - Anatomia Comparata E CitologiaMolecular Biologyoncology_oncogenicsmass spectrometrysurgical tissuesbusiness.industryCancermedicine.diseasePrimary tumor030104 developmental biologyApoptosisprotein clusteringCancer researchbreast cancer; surgical tissues; gel-based proteomics; mass spectrometry; protein clusteringbusinessProteomes
researchProduct

ΔNp63 drives metastasis in breast cancer cells via PI3K/CD44v6 axis

2016

P63 is a transcription factor belonging to the family of p53, essential for the development and differentiation of epithelia. In recent years, it has become clear that altered expression of the different isoforms of this gene can play an important role in carcinogenesis. The p63 gene encodes for two main isoforms known as TA and ΔN p63 with different functions. The role of these different isoforms in sustaining tumor progression and metastatic spreading however has not entirely been clarified. Here we show that breast cancer initiating cells express ΔNp63 isoform that supports a more mesenchymal phenotype associated with a higher tumorigenic and metastatic potential. On the contrary, the ma…

0301 basic medicineGene isoformEpithelial-Mesenchymal TransitionBreast Neoplasmsmedicine.disease_causeMetastasisMicePhosphatidylinositol 3-Kinases03 medical and health sciencesBreast cancerTumor MicroenvironmentmedicineAnimalsHumansmetastasisEpithelial–mesenchymal transitionNeoplasm MetastasisPI3K/AKT/mTOR pathwayAgedAged 80 and overTumor microenvironmentp63breast cancer initiating cellsbusiness.industryMembrane ProteinsCD44v6Middle Agedmedicine.diseasePI3K/AKT pathwayHyaluronan Receptors030104 developmental biologyOncologyDrug Resistance NeoplasmTumor progressionImmunologyCancer researchFemalebreast cancer initiating cellmetastasibusinessCarcinogenesisProto-Oncogene Proteins c-aktSignal TransductionPriority Research Paper
researchProduct

2017

Purpose BRCA1/2 mutations increase the risk of breast and prostate cancer in men. Common genetic variants modify cancer risks for female carriers of BRCA1/2 mutations. We investigated—for the first time to our knowledge—associations of common genetic variants with breast and prostate cancer risks for male carriers of BRCA1/ 2 mutations and implications for cancer risk prediction. Materials and Methods We genotyped 1,802 male carriers of BRCA1/2 mutations from the Consortium of Investigators of Modifiers of BRCA1/2 by using the custom Illumina OncoArray. We investigated the combined effects of established breast and prostate cancer susceptibility variants on cancer risks for male carriers of…

0301 basic medicineGeneticsOncologyCancer Researchmedicine.medical_specialtymedicine.diagnostic_testbusiness.industryCase-control studyGenome-wide association studyOdds ratiomedicine.disease3. Good health03 medical and health sciencesProstate cancer030104 developmental biology0302 clinical medicineBreast cancerOncology030220 oncology & carcinogenesisInternal medicinemedicineOverdiagnosisbusinessRisk assessmentGenetic testingJournal of Clinical Oncology
researchProduct

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 3…

2017

Importance: Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning.Objective: To estimate mortality, incidence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 32 cancers in 195 countries and territories from 1990 to 2015.Evidence Review: Cancer mortality was estimated using vital registration system data, cancer registry incidence data (transformed to mortality estimates using separately estimated mortality to incidence [MI] ratios), and verbal autopsy data. Cancer incidence was calculated by dividing mortality estimates through the modeled MI ratio…

0301 basic medicineGerontologyCancer ResearchPopulationArticle03 medical and health sciences0302 clinical medicineBreast cancerGlobal healthcancerMedicineDisability-adjusted life yeareducationDisease burdeneducation.field_of_studyestimate mortalityCancer preventioncancer preventionbusiness.industryMortality rate1. No povertymedicine.disease3. Good health030104 developmental biologyYears of potential life lostOncology030220 oncology & carcinogenesisbusinessearly diagnosisDemography
researchProduct

Dietary fiber and the glycemic index: a background paper for the Nordic Nutrition Recommendations 2012

2013

The aim of this study is to review recent data on dietary fiber (DF) and the glycemic index (GI), with special focus on studies from the Nordic countries regarding cardiometabolic risk factors, type 2 diabetes, cardiovascular disease, cancer, and total mortality. In this study, recent guidelines and scientific background papers or updates on older reports on DF and GI published between 2000 and 2011 from the US, EU, WHO, and the World Cancer Research Fund were reviewed, as well as prospective cohort and intervention studies carried out in the Nordic countries. All of the reports support the role for fiber-rich foods and DF as an important part of a healthy diet. All of the five identified N…

0301 basic medicineGerontologyPopulation030209 endocrinology & metabolismlcsh:TX341-641DiseaseType 2 diabetesReview ArticleOverweightLower riskVDP::Medical disciplines: 700::Health sciences: 800::Nutrition: 81103 medical and health sciences0302 clinical medicineBreast cancermedicinedietary fiber; glycemic index; Nordic Nutrition RecommendationseducationProspective cohort studyeducation.field_of_study030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryPublic Health Environmental and Occupational HealthNordic Nutrition Recommendationsmedicine.diseasedietary fiberGlycemic indexpopulation characteristicsglycemic indexmedicine.symptombusinesslcsh:Nutrition. Foods and food supplyFood ScienceFood & Nutrition Research
researchProduct

MicroRNA-33b Suppresses Epithelial-Mesenchymal Transition Repressing the MYC-EZH2 Pathway in HER2+ Breast Carcinoma

2020

Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial-mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) is a master regulator of controlling the stem cell differentiation and the cell proliferation processes. We aim to evaluate the implication of miR-33b in the EMT pathway in HER2+ breast cancer (BC) and to analyze the role of EZH2 in this process as well as the interaction between them. miR-33b is downregulated in HER2+ BC cells vs healthy controls, where EZH2 has an opposite expression in vitro and in patients' samples. The upregulation of miR-33b suppressed proliferatio…

0301 basic medicineHER2+Mama ExamenCancer ResearchmiRNA-33bCellular differentiationVimentinMYCmacromolecular substanceslcsh:RC254-28203 medical and health sciences0302 clinical medicinebreast cancerDownregulation and upregulationmicroRNAGene silencingEpithelial–mesenchymal transitionEZH2CàncerbiologyCell growthChemistryEZH2EMTlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncology030220 oncology & carcinogenesisbiology.proteinCancer research
researchProduct